Late-life dementias: does this unyielding global challenge require a broader view?
作者信息
Montine Thomas J, Larson Eric B
出版信息
JAMA. 2009 Dec 16;302(23):2593-4. doi: 10.1001/jama.2009.1863.
Abstract
摘要
相似文献
1
Late-life dementias: does this unyielding global challenge require a broader view?晚年痴呆症：这一严峻的全球性挑战是否需要更广阔的视野？
JAMA. 2009 Dec 16;302(23):2593-4. doi: 10.1001/jama.2009.1863.
2
Tarenflurbil: a shot on goal.
Lancet Neurol. 2008 Jun;7(6):468-9. doi: 10.1016/S1474-4422(08)70091-7. Epub 2008 Apr 29.
3
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.他克林对轻中度阿尔茨海默病患者认知功能下降及日常生活活动能力的影响：一项随机对照试验。
JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.
4
[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].[用于治疗阿尔茨海默病的抗淀粉样蛋白药物的研发进展。]
Nihon Yakurigaku Zasshi. 2010 Jul;136(1):15-20. doi: 10.1254/fpj.136.15.
5
Targeting nascent soluble Aβ42 for potential Alzheimer drug development.靶向新生可溶性Aβ42用于潜在的阿尔茨海默病药物研发。
J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13.
6
[Gamma-secretase inhibitors and modulators].[γ-分泌酶抑制剂和调节剂]
Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:83-7.
7
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.CHF5074，一种新型γ-分泌酶调节剂，可减轻阿尔茨海默病小鼠模型中的脑β-淀粉样蛋白病变和学习缺陷。
Br J Pharmacol. 2009 Mar;156(6):982-93. doi: 10.1111/j.1476-5381.2008.00097.x.
8
[New approaches for the development of anti-Alzheimer's disease drugs based on the cholinergic hypothesis and amyloid hypothesis].基于胆碱能假说和淀粉样蛋白假说的抗阿尔茨海默病药物研发新方法
Nihon Yakurigaku Zasshi. 2008 May;131(5):338-40. doi: 10.1254/fpj.131.338.
9
Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.与 γ-分泌酶相互作用治疗阿尔茨海默病：从抑制到调节。
Curr Med Chem. 2011;18(35):5430-47. doi: 10.2174/092986711798194351.
10
Treatments for Alzheimer's disease emerge.治疗阿尔茨海默病的方法出现了。
Science. 2021 Aug 6;373(6555):624-626. doi: 10.1126/science.abi6401.
引用本文的文献
1
Leveraging neuropathological data in pharmacoepidemiology: A promising approach for dementia prevention?在药物流行病学中利用神经病理学数据：预防痴呆症的一种有前景的方法？
Pharmacoepidemiol Drug Saf. 2021 Jan;30(1):1-3. doi: 10.1002/pds.5068. Epub 2020 Jun 29.
2
Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea.韩国脑库脑尸检标准化操作程序提案指南
Yonsei Med J. 2017 Sep;58(5):1055-1060. doi: 10.3349/ymj.2017.58.5.1055.
3
Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.阿尔茨海默病研究的最新进展，第3部分：诊断与治疗
J Alzheimers Dis. 2017;57(3):645-665. doi: 10.3233/JAD-160907.
4
Somatic comorbidities and Alzheimer's disease treatment.躯体共病与阿尔茨海默病治疗。
Neurol Sci. 2013 Sep;34(9):1581-9. doi: 10.1007/s10072-013-1290-3. Epub 2013 Feb 1.
5
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).额颞叶变性的药物研发优势（额颞叶变性系列之三：下一个治疗前沿）。
Alzheimers Dement. 2013 Mar;9(2):189-98. doi: 10.1016/j.jalz.2012.03.003. Epub 2012 Oct 10.
6
Anatomic and clinical pathology of cognitive impairment and dementia.认知障碍和痴呆的解剖和临床病理学。
J Alzheimers Dis. 2013;33 Suppl 1(0 1):S181-4. doi: 10.3233/JAD-2012-129032.
7
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.国家老龄化研究所-阿尔茨海默病协会关于阿尔茨海默病神经病理学评估的指南。
Alzheimers Dement. 2012 Jan;8(1):1-13. doi: 10.1016/j.jalz.2011.10.007.
8
Ecology of the aging human brain.衰老人类大脑的生态学
Arch Neurol. 2011 Aug;68(8):1049-56. doi: 10.1001/archneurol.2011.157.
9
Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.脑脊液和血浆生物标志物在神经退行性疾病和轻度认知障碍诊断中的作用。
Curr Neurol Neurosci Rep. 2011 Oct;11(5):455-63. doi: 10.1007/s11910-011-0212-0.
10
Elevated natriuretic peptide levels and cognitive function in community-dwelling older adults.社区居住的老年人中心钠肽水平升高与认知功能。
Am J Med. 2011 Jul;124(7):670.e1-8. doi: 10.1016/j.amjmed.2011.02.027.
本文引用的文献
1
Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.血浆瘦素水平与阿尔茨海默病发病及脑老化 MRI 测量指标的相关性。
JAMA. 2009 Dec 16;302(23):2565-72. doi: 10.1001/jama.2009.1836.
2
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.他克林对轻中度阿尔茨海默病患者认知功能下降及日常生活活动能力的影响：一项随机对照试验。
JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.
3
Ageing populations: the challenges ahead.老龄化人口：未来的挑战。
Lancet. 2009 Oct 3;374(9696):1196-208. doi: 10.1016/S0140-6736(09)61460-4.
4
Central obesity and increased risk of dementia more than three decades later.中心性肥胖与三十多年后患痴呆症风险增加。
Neurology. 2009 Mar 17;72(11):1030-1; author reply 1031.
5
Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial.体育活动对有患阿尔茨海默病风险的老年人认知功能的影响：一项随机试验。
JAMA. 2008 Sep 3;300(9):1027-37. doi: 10.1001/jama.300.9.1027.
6
Gamma-secretase inhibition and modulation for Alzheimer's disease.γ-分泌酶抑制与调节在阿尔茨海默病中的应用
Curr Alzheimer Res. 2008 Apr;5(2):158-64. doi: 10.2174/156720508783954767.
7
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.β-淀粉样蛋白的可溶性寡聚体损害突触可塑性和行为。
Behav Brain Res. 2008 Sep 1;192(1):106-13. doi: 10.1016/j.bbr.2008.02.016. Epub 2008 Feb 17.
8
Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study.65岁及以上人群中血压与痴呆症风险之间的年龄差异关联：一项基于社区的前瞻性队列研究。
J Am Geriatr Soc. 2007 Aug;55(8):1161-7. doi: 10.1111/j.1532-5415.2007.01233.x.
9
Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older.运动与65岁及以上人群患痴呆症的风险降低有关。
Ann Intern Med. 2006 Jan 17;144(2):73-81. doi: 10.7326/0003-4819-144-2-200601170-00004.
10
Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study.他汀类药物治疗与老年人痴呆风险：一项基于社区的前瞻性队列研究。
Neurology. 2004 Nov 9;63(9):1624-8. doi: 10.1212/01.wnl.0000142963.90204.58.
Zotero 插件